denosumab
FDA approves Sandoz’s denosumab biosimilars
March 6, 2024Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
Boan Biotech completes enrolment for phase 3 study of Denosumab
January 15, 2024Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab
Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …
Amgen’s Prolia achieves positive top-line Phase III results after 12 months
August 30, 2016Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III
Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Amgen bone cancer drug Xgeva approved in Europe
July 18, 2011Sales and Marketing Amgen, Prolia, Xgeva, denosumab
Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …
Amgen aims for oncology expansion and a wider denosumab license
January 12, 2011Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib
Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …
Denosumab approved for bone cancer use
November 19, 2010Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab
Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
